| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.15 | 0.001 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.001 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.002 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.002 |